Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.
While attending the 2025 World Conference on Genitourinary Cancers (World GU), Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke with various experts and presenters about critical developments that may improve the treatment of patients with different genitourinary malignancies. Bupathi is executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and genitourinary cancers. Garmezy is associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at SCRI and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers.
In this episode, Bupathi and Garmezy explored the conference halls to chat with several colleagues and peers who presented on topics related to the care of those with prostate cancer, kidney cancer, bladder cancer, and other genitourinary malignancies. The hosts exchanged ideas on how to elevate the quality of care for these patients in a community-based setting with the following attendees:
Stay up to date on recent advances in the multidisciplinary approach to cancer.